265 related articles for article (PubMed ID: 25344788)
1. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
2. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.
Rosenzwajg M; Churlaud G; Mallone R; Six A; Dérian N; Chaara W; Lorenzon R; Long SA; Buckner JH; Afonso G; Pham HP; Hartemann A; Yu A; Pugliese A; Malek TR; Klatzmann D
J Autoimmun; 2015 Apr; 58():48-58. PubMed ID: 25634360
[TBL] [Abstract][Full Text] [Related]
3. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial.
Todd JA; Evangelou M; Cutler AJ; Pekalski ML; Walker NM; Stevens HE; Porter L; Smyth DJ; Rainbow DB; Ferreira RC; Esposito L; Hunter KM; Loudon K; Irons K; Yang JH; Bell CJ; Schuilenburg H; Heywood J; Challis B; Neupane S; Clarke P; Coleman G; Dawson S; Goymer D; Anselmiova K; Kennet J; Brown J; Caddy SL; Lu J; Greatorex J; Goodfellow I; Wallace C; Tree TI; Evans M; Mander AP; Bond S; Wicker LS; Waldron-Lynch F
PLoS Med; 2016 Oct; 13(10):e1002139. PubMed ID: 27727279
[TBL] [Abstract][Full Text] [Related]
5. Continuum model of T-cell avidity: Understanding autoreactive and regulatory T-cell responses in type 1 diabetes.
Jaberi-Douraki M; Pietropaolo M; Khadra A
J Theor Biol; 2015 Oct; 383():93-105. PubMed ID: 26271890
[TBL] [Abstract][Full Text] [Related]
6. Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.
Truman LA; Pekalski ML; Kareclas P; Evangelou M; Walker NM; Howlett J; Mander AP; Kennet J; Wicker LS; Bond S; Todd JA; Waldron-Lynch F
BMJ Open; 2015 Dec; 5(12):e009799. PubMed ID: 26646829
[TBL] [Abstract][Full Text] [Related]
7. IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
Long SA; Buckner JH; Greenbaum CJ
Clin Immunol; 2013 Dec; 149(3):324-31. PubMed ID: 23499139
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs.
Grinberg-Bleyer Y; Saadoun D; Baeyens A; Billiard F; Goldstein JD; Grégoire S; Martin GH; Elhage R; Derian N; Carpentier W; Marodon G; Klatzmann D; Piaggio E; Salomon BL
J Clin Invest; 2010 Dec; 120(12):4558-68. PubMed ID: 21099113
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-35 administration counteracts established murine type 1 diabetes--possible involvement of regulatory T cells.
Singh K; Kadesjö E; Lindroos J; Hjort M; Lundberg M; Espes D; Carlsson PO; Sandler S; Thorvaldson L
Sci Rep; 2015 Jul; 5():12633. PubMed ID: 26224624
[TBL] [Abstract][Full Text] [Related]
10. T regulatory lymphocytes in type 1 diabetes: Impaired CD25 expression and IL-2 induced STAT5 phosphorylation in pediatric patients.
Parackova Z; Kayserova J; Danova K; Sismova K; Dudkova E; Sumnik Z; Kolouskova S; Lebl J; Stechova K; Sediva A
Autoimmunity; 2016 Dec; 49(8):523-531. PubMed ID: 27560779
[TBL] [Abstract][Full Text] [Related]
11. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.
Dong S; Hiam-Galvez KJ; Mowery CT; Herold KC; Gitelman SE; Esensten JH; Liu W; Lares AP; Leinbach AS; Lee M; Nguyen V; Tamaki SJ; Tamaki W; Tamaki CM; Mehdizadeh M; Putnam AL; Spitzer MH; Ye CJ; Tang Q; Bluestone JA
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34324441
[TBL] [Abstract][Full Text] [Related]
12. CD11a/ICAM-1 blockade combined with IL-2 targeting therapy causes a paradoxical acceleration of type 1 diabetes.
Brenu EW; Bartley TJ; Wright CM; Hamilton-Williams EE
Immunol Cell Biol; 2017 Oct; 95(9):803-813. PubMed ID: 28611472
[TBL] [Abstract][Full Text] [Related]
13. Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes.
Turner MS; Isse K; Fischer DK; Turnquist HR; Morel PA
Diabetologia; 2014 Jul; 57(7):1428-36. PubMed ID: 24737163
[TBL] [Abstract][Full Text] [Related]
14. Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance.
Gupta S; Cerosaletti K; Long SA
Clin Immunol; 2014 Apr; 151(2):146-54. PubMed ID: 24576418
[TBL] [Abstract][Full Text] [Related]
15. Effector T Cell Resistance to Suppression and STAT3 Signaling during the Development of Human Type 1 Diabetes.
Ihantola EL; Viisanen T; Gazali AM; Näntö-Salonen K; Juutilainen A; Moilanen L; Rintamäki R; Pihlajamäki J; Veijola R; Toppari J; Knip M; Ilonen J; Kinnunen T
J Immunol; 2018 Aug; 201(4):1144-1153. PubMed ID: 30006377
[TBL] [Abstract][Full Text] [Related]
16. How GRAIL controls Treg function to maintain self-tolerance.
Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
[TBL] [Abstract][Full Text] [Related]
17. Low-dose IL-2 therapy in autoimmune diseases: An update review.
Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
[TBL] [Abstract][Full Text] [Related]
18. IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.
Diaz-de-Durana Y; Lau J; Knee D; Filippi C; Londei M; McNamara P; Nasoff M; DiDonato M; Glynne R; Herman AE
PLoS One; 2013; 8(10):e78483. PubMed ID: 24205242
[TBL] [Abstract][Full Text] [Related]
19. Anti-cytokine therapies in T1D: Concepts and strategies.
Nepom GT; Ehlers M; Mandrup-Poulsen T
Clin Immunol; 2013 Dec; 149(3):279-85. PubMed ID: 23510726
[TBL] [Abstract][Full Text] [Related]
20. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
